Tecovirimat

Tecovirimat Chemische Eigenschaften,Einsatz,Produktion Methoden

• Verwenden

  Tecovirimat is an orally bioavailable antipoxvirus compound inhibits extracellular virus formation and protects mice from lethal orthopoxvirus, including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), and variola viruses.

• Pharmakokinetik

  At the recommended oral dosage of 600 mg every 12 hours administered in healthy adults weighing less than 120 kg, the mean steady-state values of tecovirimat AUC0-24hr, Cmax, and Ctau/trough are 29816 hr?¤ng/mL (n, CV: 43, 34%), 2159 ng/mL (n, CV: 46, 32%), and 845 ng/mL (n, CV: 45, 47%), respectively. At the recommended intravenous dosage of 200 mg every 12 hours administered by IV infusion over 6 hours in healthy adults, the mean steady-state values of tecovirimat AUC0-24hr, Cmax, and Cmin are 39405 hr.ng/mL (n, CV: 22, 23%), 2630 ng/mL (n, CV: 22, 22%), and 747 ng/mL (n, CV: 22, 29%). Refer to Table 7 for pharmacokinetic parameters of tecovirimat. Tecovirimat steady-state is achieved by Day 4-6.

• Nebenwirkungen

  Common side effects of TPOXX (Tecovirimat) include: headache, nausea, abdominal pain, and vomiting.
  TPOXX (Tecovirimat) may cause serious side effects, including: hives, difficulty breathing, and swelling of your face, lips, tongue, or throat.

Tecovirimat Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(64)Suppliers

816458-31-8, Tecovirimat Verwandte Suche: